Form 4: Vera Therapeutics COO Acquires 160,000 Stock Options

David Lee Johnson, COO of Vera Therapeutics, acquired 160,000 stock options on July 1, 2024, according to a Form 4 filing.

Summary

• David Lee Johnson, the Chief Operating Officer of Vera Therapeutics, Inc., filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on July 1, 2024, where Johnson acquired 160,000 stock options.
• The exercise price of these options is $36.29.
• The options vest over time, with 1/4 vesting on July 1, 2025, and the remaining 3/48 vesting monthly thereafter, contingent upon continuous service.
• The expiration date for these options is June 30, 2034.
• Following the reported transaction, Johnson directly owns 160,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing related to stock option grants. While option grants can be seen as a positive incentive for management, the filing itself doesn't inherently indicate positive or negative sentiment.

Positives

• The acquisition of stock options by the COO could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the transactions of company officers and directors, which can be indicative of their confidence in the company's prospects.

Stakeholder Impact

• Shareholders may view the stock option grant as an incentive for the COO to drive company performance.

Key Dates